Cedar allergy is a seasonal allergy brought on by an allergic reaction to the pollen from mountain cedar trees. Symptoms include runny nose, itchy and watery eyes, nasal blockage and sneezing. Some suffers also complain of fatigue, mild headache, facial discomfort, sore throat, partial loss of smell and the sensation of ear plugging. Treatment includes antihistamines and decongestants.
Pharmaceutical and Healthcare latest pipeline guide Cedar Pollen Allergy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cedar Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Cedar Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Report Coverage
- Cedar Pollen Allergy - Overview
- Cedar Pollen Allergy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cedar Pollen Allergy - Therapeutics Assessment
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cedar Pollen Allergy - Companies Involved in Therapeutics Development
- ALK-Abello A/S
- Astellas Pharma Inc
- Japan Tobacco Inc
- REGiMMUNE Corp
- Stallergenes Greer plc
For more information about this report visit http://www.researchandmarkets.com/research/6rhpz3/cedar_pollen